10 recalls found for Major Pharmaceuticals. Check if any of your products are affected.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg on October 10, 2025, due to failed stability testing. The recall affects capsules packaged in blister packs and sold nationwide. Consumers must stop using the product immediately and seek guidance from healthcare providers.
Major Pharmaceuticals recalled 2,064 blister packs of Chlorpromazine Hydrochloride Tablets on September 12, 2025. The recall follows the discovery of N-Nitroso Desmethyl Chlorpromazine exceeding safe limits. Consumers must stop using this product immediately and consult healthcare providers for guidance.
Major Pharmaceuticals announced a recall of 1,256 blister packs of Chlorpromazine Hydrochloride Tablets on September 12, 2025. The recall stems from the presence of N-Nitroso Desmethyl Chlorpromazine above safe intake levels. Consumers must stop using the product immediately and contact their healthcare provider for guidance.
Major Pharmaceuticals recalled 1,394 blister packs of Chlorpromazine Hydrochloride Tablets due to contamination concerns. The recall occurred on September 12, 2025, after the FDA found N-Nitroso Desmethyl Chlorpromazine above acceptable limits. Consumers should stop using these tablets and seek guidance from healthcare providers.
Major Pharmaceuticals recalled 506 blister packs of Chlorpromazine Hydrochloride tablets on September 12, 2025. The recall stems from CGMP deviations due to the presence of N-Nitroso Desmethyl Chlorpromazine above safe limits. Consumers should stop using the product immediately and consult healthcare providers.
Major Pharmaceuticals recalled 866 blister packs of Chlorpromazine Hydrochloride Tablets on September 12, 2025. The recall follows the detection of N-Nitroso Desmethyl Chlorpromazine above safe limits. The affected products were distributed nationwide and are classified as a Class II hazard.
Major Pharmaceuticals recalled Sulfamethoxazole and Trimethoprim tablets on September 2, 2025, due to contamination concerns. A foreign substance was found in the packaging material, although the tablets themselves remain unaffected. Consumers should stop using the product immediately and consult healthcare providers.
Cardinal Health recalled Sulfamethoxazole and Trimethoprim tablets on September 2, 2025, due to contamination risks. A specific lot contained a foreign substance with a detected micro-organism, although no contamination was found on the tablets. Consumers must stop using the product immediately and seek guidance from healthcare providers.
Major Pharmaceuticals recalled 26,628 cartons of Carvedilol Tablets on August 20, 2025. The recall stems from N-Nitroso Carvedilol Impurity-1 levels exceeding FDA limits. Consumers should stop using the product immediately and consult their healthcare provider.